Clinical Practice Decisions in Endocrine Therapy

REFERENCES

• Lamerato, L.; Havstad, S.; Gandhi, S.; Jones, D.; Chlebowski, R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 2005, 23(16S), 62s. Abstract 738.
   Google Scholar
• Lê, M.G.; Arriagada, R.; Spielmann, M.; Guinebretière, J-M; Rochard, F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002, 94(11), 2813–2820.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472), 1687–1717.
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K.N.; Goldhirsch, A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26), 2747–2757.
   PubMed Web of Science ®Google Scholar
• Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M., Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453), 60–62.
   PubMed Web of Science ®Google Scholar
• The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Forbes, J.F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J.S.; Baum, M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1), 45–53.
   PubMed Web of Science ®Google Scholar
• Coates, A.S.; Keshaviah, A.; Thürlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Colleoni, M.; Láng, I.; Del Mastro, L.; Smith, I.; Chirgwin, J.; Nogaret, J.M.; Pienkowski, T.; Wardley, A.; Jakobsen, E.H.; Price, K.N.; Goldhirsch, A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25(5), 486–492.
   PubMed Web of Science ®Google Scholar
• BIG 1-98 Collaborative Group, Mouridsen, H.; Giobbie-Hurder, A.; Goldhirsch, A.; Thürlimann, B.; Paridaens, R.; Smith, I.; Mauriac, L.; Forbes, J.F.; Price, K.N.; Regan, M.M.; Gelber, R.D.; Coates, A.S. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361(8), 766–776.
   PubMed Web of Science ®Google Scholar
• Coombes, R.C.; Kilburn, L.S.; Snowdon, C.F.; Paridaens, R.; Coleman, R.E.; Jones, S.E.; Jassem, J.; Van de Velde, C.J.; Delozier, T.; Alvarez, I.; Del Mastro, L., Ortmann, O.; Diedrich, K.; Coates, A.S.; Bajetta, E.; Holmberg, S.B.; Dodwell, D.; Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi, G.; Forbes, J.; Castiglione, M.; Stuart, N.; Stewart, A.; Fallowfield, L.J.; Bertelli, G.; Hall, E.; Bogle, R.G.; Carpentieri, M.; Colajori, E.; Subar, M.; Ireland, E.; Bliss, J.M.; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369(9561), 559–570.
   PubMed Web of Science ®Google Scholar
• Jakesz, R.; Gnant, M.; Greil, R.; Tausch, C.; Samonigg, H.; Kwasny, W.; Kubista, E.; Stierer, M.; Luschin, G.; Mittlboeck, M. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005, 94(Suppl 1), S10. Abstract 13.
   Google Scholar
• Jakesz, R.; Gnant, M.; Greil, R.; Tausch, C.; Samonigg, H.; Kwansy, W.; Kubista, E.; Stierer, M.; Luschin, G.; Rucklinger, E.; Mittibock, M. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res 2009, 69(Suppl 2), 67s. Abstract 14.
   Web of Science ®Google Scholar
• Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97(17), 1262–1271.
   PubMed Web of Science ®Google Scholar
• Rutqvist, L.E.; Johansson, H.; Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007, 46(2), 133–145.
   PubMed Web of Science ®Google Scholar
• Dignam, J.J.; Dukic, V.; Anderson, S.J.; Mamounas, E.P.; Wickerham, D.L.; Wolmark, N. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 2009, 116(3), 595–602.
   PubMed Web of Science ®Google Scholar
• Cuzick, J.; Wale, C., on behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Breast Can Res Treat 2006, 100(Suppl 1), S24. Abstract 104.
   Google Scholar
• Duffy, S., on behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years follow-up. Breast Can Res Treat 2006, 100(Suppl 1), S190. Abstract 4055.
   Google Scholar
• Decensi, A.; Maisonneuve, P., Rotmensz, N.; Bettega, D.; Costa, A.; Sacchini, V.; Salvioni, A.; Travaglini, R.; Oliviero, P.; D'Aiuto, G.; Gulisano, M.; Gucciardo, G.; del Turco, M.R.; Pizzichetta, M.A.; Conforti, S.; Bonanni, B.; Boyle, P.; Veronesi, U.; Italian Tamoxifen Study Group. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005, 111(5), 650–656.
   PubMed Web of Science ®Google Scholar
• Powles, T.; Eeles, R.; Ashley, S.; Easton, D.; Chang, J.; Dowsett, M.; Tidy, A.; Viggers, J.; Davey, J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998, 352(9122), 98–101.
   PubMed Web of Science ®Google Scholar
• Chan, A.; Speers, C.; O'Reilly, S.; Pickering, R.; Chia, S.; Chia, S. Adherence of adjuvant hormonal therapies in post-menopausal hormone receptor positive (HR+) early stage breast cancer: a population based study from British Columbia. Cancer Res 2009, 69(24 Suppl). Abstract 36.
   Web of Science ®Google Scholar
• Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T.; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359(9324), 2131–2139. Erratum in: Lancet 2002;360(9344):1520.
   PubMed Web of Science ®Google Scholar
• Dowsett, M.; Cuzick, J.; Wale, C.; Howell, T.; Houghton, J.; Baum, M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005, 23(30), 7512–7517.
   PubMed Web of Science ®Google Scholar
• Mauriac, L.; Keshaviah, A.; Debled, M.; Mouridsen, H.; Forbes, J.F.; Thürlimann, B.; Paridaens, R.; Monnier, A.; Láng, I.; Wardley, A.; Nogaret, J.M.; Gelber, R.D.; Castiglione-Gertsch, M.; Price, K.N.; Coates, A.S.; Smith, I.; Viale, G.; Rabaglio, M.; Zabaznyi, N.; Goldhirsch, A.; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007, 18(5), 859– 867.
   PubMed Web of Science ®Google Scholar
• Thürlimann, B.; BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. Update of the BIG 1-98 primary core analysis. 11th International St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer; March 11–14, 2009; St. Gallen, Switzerland. Abstract 0161.
   Google Scholar
• Jones, S.E.; Seynaeve, C.; Hasenburg, A.; Rae, D.; Vannetzel, J-M; Paridaens, R.; Markopoulos, C.; Hozumi, Y.; Putter, H.; Hille, E.; Kieback, D.; Asmar, L.; Smeets, J.; Urbanski, R.; Bartlett, M.J.S.; van de Velde, C.J.H. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res 2009; 69(Suppl 2), 67s. Abstract 15.
   Web of Science ®Google Scholar
• Coombes, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S.E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A.S.; Bajetta, E.; Dodwell, D.; Coleman, R.E.; Fallowfield, L.J.; Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C.F.; Carpentieri, M.; Massimini, G.; Bliss, J.M.; van de Velde, C.; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11), 1081–1092.
   PubMed Web of Science ®Google Scholar
• Rea, D.; Hasenburg, A.; Seynaeve, C.; Jones, S.E.; Vannetzel, J-M; Paridaens, R.; Markopoulos, C.; Hozumi, Y.; Putter, H.; Hille, E.; Asmar, L.; Urbanski, R.; van de Velde, C.H.; Bartlett, J.M.S.; Smeets, J.; Kieback, D.G. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase iii trial in postmenopausal women with hormone-sensitive early breast cancer. 32nd San Antonio Breast Cancer Symposium; December 10-13, 2009, San Antonio, Texas. Abstract 11.
   Google Scholar
• Jassem, J.; International Exemestane Study Group. Intergroup Exemestane Study mature analysis: overall survival data. Anticancer Drugs 2008, 19(Suppl 1), S3–S7.
   PubMedGoogle Scholar
• Jonat, W.; Gnant, M.; Boccardo, F.; Kaufmann, M.; Rubagotti, A.; Zuna, I.; Greenwood, M.; Jakesz, R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7(12), 991–996.
   PubMed Web of Science ®Google Scholar
• Mansell, J.; Monypenny, I.J.; Skene, A.I.; Abram, P.; Carpenter, R.; Gattuso, J.M.; Wilson, C.R.; Angerson, W.J.; Doughty, J.C. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 2009 Sep, 117(1), 91–98.
   PubMed Web of Science ®Google Scholar
• Houghton, J., on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. J Clin Oncol 2005, 23(16S), 24S. Abstract 582.
   PubMedGoogle Scholar
• Goss, P.E.; Ingle, J.N.; Pater, J.L.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Tu, D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008, 26(12), 1948–1955.
   PubMed Web of Science ®Google Scholar
• Ingle, J.N.; Tu, D.; Pater, J.L.; Muss, H.B.; Martino, S.; Robert, N.J.; Piccart, M.J.; Castiglione, M.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Goss, P.E. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008, 19(5), 877–882.
   PubMed Web of Science ®Google Scholar
• Crivellari, D.; Sun, Z.; Coates, A.S.; Price, K.N.; Thürlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.J.; Castiglione-Gertsch, M.; Gelber, R.D.; Colleoni, M.; Láng, I.; Del Mastro, L.; Gladieff, L.; Rabaglio, M.; Smith, I.E.; Chirgwin, J.H.; Goldhirsch, A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008, 26(12), 1972–1979.
   PubMed Web of Science ®Google Scholar
• Muss, H.B.; Tu, D.; Ingle, J.N.; Martino, S.; Robert, N.J.; Pater, J.L.; Whelan, T.J.; Palmer, M.J.; Piccart, M.J.; Shepherd, L.E.; Pritchard, K.I.; He, Z.; Goss, P.E. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008, 26(12), 1956–1964.
   PubMed Web of Science ®Google Scholar
• Goss, P.; Ingle, J.; Martino, S.; Robert, N.; Muss, H.; Shepherd, L.; Pritchard, K.; Livingston, R.; Davidson, N.; Perez, E.; Cameron, D.; Whelan, T.; Palmer, M.; Tu, D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial. Cancer Res 2009, 69(24 Suppl). Abstract 13.
   Web of Science ®Google Scholar
• Bardou, V.J.; Arpino, G.; Elledge, R.M.; Osborne, C.K.; Clark, G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21(10), 1973–1979.
   PubMed Web of Science ®Google Scholar
• Viale, G.; Giobbie-Hurder, A. Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2007, 100(Suppl 1), S17. Abstract 64.
   Google Scholar
• Rasmussen, B.B.; Regan, M.M.; Lykkesfeldt, A.E.; Dell'Orto, P.; Del Curto, B.; Henriksen, K.L.; Mastropasqua, M.G.; Price, K.N.; Méry, E.; Lacroix-Triki, M.; Braye, S.; Altermatt, H.J.; Gelber, R.D.; Castiglione-Gertsch, M.; Goldhirsch, A.; Gusterson, B.A.; Thürlimann, B.; Coates, A.S.; Viale, G.; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9(1), 23–28.
   PubMed Web of Science ®Google Scholar
• Dowsett, M.; Allred, C.; Knox, J.; Quinn, E.; Salter, J.; Wale, C.; Cuzick, J.; Houghton, J.; Williams, N.; Mallon, E.; Bishop, H.; Ellis, I.; Larsimont, D.; Sasano, H.; Carder, P.; Cussac, A.L.; Knox, F.; Speirs, V.; Forbes, J.; Buzdar, A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26(7), 1059–1065.
   PubMed Web of Science ®Google Scholar
• Viale, G.; Giobbie-Hurder, A.; Regan, M.M.; Coates, A.S.; Mastropasqua, M.G.; Dell'Orto, P.; Maiorano, E.; MacGrogan, G.; Braye, S.G.; Ohlschlegel, C.; Neven, P.; Orosz, Z.; Olszewski, W.P.; Knox, F.; Thürlimann, B.; Price, K.N.; Castiglione-Gertsch, M.; Gelber, R.D.; Gusterson, B.A.; Goldhirsch, A.; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008, 26(34), 5569–5575.
   PubMed Web of Science ®Google Scholar
• Rae, J.M.; Sikora, M.J.; Henry, N.L.; Li, L.; Kim, S.; Oesterreich, S.; Skaar, T.; Nguyen, A.T.; Desta, Z.; Storniolo, A.M.; Flockhart, D.A.; Hayes, D.F.; Stearns, V. Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy. Breast Cancer Res Treat 2007, 106(Suppl 1), S21. Abstract 77.
   Google Scholar
• Schroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U.M.; Simon, W.; Eichelbaum, M.; Brauch, H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007, 25(33), 5187–5193.
   PubMed Web of Science ®Google Scholar
• Goetz, M.P.; Knox, S.K.; Suman, V.J.; Rae, J.M.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L., Weinshilboum, R.M.; Fritcher, E.G.; Nibbe, A.M.; Desta, Z.; Nguyen, A.; Flockhart, D.A.; Perez, E.A.; Ingle, J.N. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101(1), 113–121.
   PubMed Web of Science ®Google Scholar
• Goetz, M.; Berry, D.; Klein, T. and International Tamoxifen Pharmacogenomics Consortium. Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium. Cancer Res 2009, 69(24 Suppl). Abstract 33.
   PubMed Web of Science ®Google Scholar
• Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Ho, H.; Lee, K.H.; Skaar, T.; Storniolo, A.M.; Li, L.; Araba, A.; Blanchard, R.; Nguyen, A.; Ullmer, L.; Hayden, J.; Lemler, S.; Weinshilboum, R.M.; Rae, J.M.; Hayes, D.F.; Flockhart, D.A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97(1), 30–39.
   PubMed Web of Science ®Google Scholar
• Minami, H.; Ohsumi, S.; Nakamura, S.; Inaji, H.; Takenoshita, S.; Fujiwara, Y.; Iino, Y.; Woo, M.; Tanii, H.; Tominaga, T.; Shigemitsu, T.; CGS 20267 Collaborative Study Group. Impact of CYP2A6 genotype on pharmacokinetics, safety and efficacy of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1), S113. Abstract 2084.
   PubMedGoogle Scholar
• Bonanni, B.; Macis, D.; Maisonneuve, P.; Johansson, H.A.; Gucciardo, G.; Oliviero, P.; Travaglini, R.; Muraca, M.G.; Rotmensz, N.; Veronesi, U.; Decensi, A.U. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006, 24(22), 3708–3709.
   PubMed Web of Science ®Google Scholar
• Bonanni, B.; Maisonneuve, P.; Johansson, H.; Macis, D.; Serrano, D.; Guerrieri-Gonzaga, A.; Basso, D.; Zambon, C.; Plebani, M.; Nicoloff, M.; Fontecha, M.; Hillman, G.; Wieczorek, L.; Rotmensz, N.; Decensi A. Risk stratification based on the CYP2D6 tamoxifen metabolizing gene within the Italian tamoxifen prevention trial. Breast Cancer Res Treat 2007, 106(Suppl 1), S9. Abstract 29.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Version 1.2006. December 10, 2005.
   Google Scholar
• Winer, E.P.; Hudis, C.; Burstein, H.J.; Wolff, A.C.; Pritchard, K.I.; Ingle, J.N.; Chlebowski, R.T.; Gelber, R.; Edge, S.B.; Gralow, J.; Cobleigh, M.A.; Mamounas, E.P.; Goldstein, L.J.; Whelan, T.J.; Powles, T.J.; Bryant, J.; Perkins, C.; Perotti, J.; Braun, S.; Langer, A.S.; Browman, G.P.; Somerfield, M.R. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol. 2005, 23(3), 619–629.
   PubMed Web of Science ®Google Scholar
• Goldhirsch, A.; Wood, W.C.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J.; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18(7), 1133–1144.
   PubMed Web of Science ®Google Scholar
• Diagnosis and treatment of patients with primary and metastatic breast cancer. Adjuvant endocrine therapy in postmenopausal patients. Available at: http://www.ago-online.de/_download/unprotected/g_mamma_10_1_0_e_02_adj_endo_postmenopausal.pdf. Accessed June 1, 2010.
   Google Scholar
• Pestalozzi, B.C.; Luporsi-Gely, E.; Jost, L.M.; Bergh, J.; ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2005, 16(Suppl 1), i7–i9.
   PubMedGoogle Scholar
• Goldhirsch, A.; Ingle, J.N.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J.; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8), 1319–1329.
   PubMed Web of Science ®Google Scholar